Tazeen Ahmad
BofA Securities, Research Division

Good afternoon. Welcome back to the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I am one of the senior biotech analysts here at the bank. It's my pleasure to have our next presenting company, Belite Bio. On stage with us, we have several members from the management team. Speaking for the team today will be Tom Lin, who is Chief Executive Officer; as well as Nathan Mata, who is Chief Scientific Officer. Gentlemen, thank you for making the trip to Las Vegas. Tom, especially, I think you had a long flight over. So I really appreciate you visiting us.

Yu-Hsin Lin
Chairman of the Board of Directors & CEO

Happy to be here. Pleasure to be here. Thanks for the opportunity.

Tazeen Ahmad
BofA Securities, Research Division

So for those who may not be as familiar with Belite, I thought maybe it would be good to give a couple of minute overview of the company, the platform, and then we can go into your lead program in Stargardt.

Nathan L. Mata
Chief Scientific Officer

So you want to overview -- I'm sorry, overview of the program in Stargardt disease.

Tazeen Ahmad
BofA Securities, Research Division

Just over the company, overview of the company itself.

Nathan L. Mata
Chief Scientific Officer

Overview of the company, yes.

Yu-Hsin Lin
Chairman of the Board of Directors & CEO

All right. So we are an ophthalmology or retinal focused company. The company spun out from